How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

887 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study. (Abstract)

Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study. This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined adverse events (AEs (...) ) potentially arising from worsening of Parkinson disease motor symptoms with capsules. Secondary outcomes included frequency of AEs/serious AEs. Efficacy outcomes included Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI-10), and Mattis Dementia Rating Scale (MDRS).Five hundred eighty-three patients were randomized to rivastigmine capsules (n = 295) or patch (n = 288). Incidence of predefined AEs was 36.1% for capsules, 31.9% for patch

2014 Clinical neuropharmacology Controlled trial quality: uncertain

82. Cognitive Function in Early Clinical Phase Huntington Disease after Rivastigmine Treatment. (Abstract)

Cognitive Function in Early Clinical Phase Huntington Disease after Rivastigmine Treatment. In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected (...) to be impaired in early phase HD.Eighteen (18) HD patients entered the study and were randomly allocated to the rivastigmine and placebo group. All subjects underwent neuropsychological assessment at baseline. Follow-up neuropsychological assessment was applied after 6 months of rivastigmine or placebo treatment. Eighteen (18) healthy controls entered the study to control for practice effect and underwent neuropsychological assessment at baseline and after 6 months, without treatment. The neuropsychological

2014 Psychiatria Danubina Controlled trial quality: uncertain

83. Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease. Full Text available with Trip Pro

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease. Alzheimer's disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study aimed to determine the effects of two formulations of RV [transdermal

2014 Frontiers in aging neuroscience Controlled trial quality: predicted high

84. Rivastigmine Transdermal Patch and Physical Exercises for Alzheimer's Disease: A Randomized Clinical Trial. (Abstract)

Rivastigmine Transdermal Patch and Physical Exercises for Alzheimer's Disease: A Randomized Clinical Trial. To determine the effects of rivastigmine patch associated with physical exercise versus rivastigmine patch alone in quality of life (QOL), cognition, activities of daily living (ADL) and functional mobility in Alzheimer's disease (AD)subjects.A randomized, controlled, single-blinded trial was conducted in 40 patients with mild to moderate stages of AD. All patients were daily treated (...) with rivastigmine transdermal patch at a stable dose of 4.6 mg and randomized into two groups: physical exercises or control. The exercise program consisted of aerobic, flexibility, strength and balance movements, twice a week for 6 months. Main outcomes were Quality of Life in Alzheimer's disease scale (QOL), Activities of Daily Living Questionnaire (ADL), Mini-Mental State Examination (MMSE) and "Time Up and Go Test".Thirty-four patients completed the study. After 6 months, there was a significant improvement

2014 Current Alzheimer research Controlled trial quality: uncertain

85. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. (Abstract)

A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. To evaluate in a pilot single-blind randomized controlled clinical trial the efficacy of an integrated treatment with rivastigmine transdermal patch (RTP) and cognitive stimulation (CS) in Alzheimer's disease (AD) patients at 6-month follow-up.We enrolled 90 patients with an age ≥65 years admitted to the outpatient Alzheimer's

2014 International Journal of Geriatric Psychiatry Controlled trial quality: uncertain

86. Rivastigmine patch and massage for Alzheimer's disease patients. (Abstract)

Rivastigmine patch and massage for Alzheimer's disease patients. 23551354 2013 11 05 2015 11 19 1447-0594 13 2 2013 Apr Geriatrics & gerontology international Geriatr Gerontol Int Rivastigmine patch and massage for Alzheimer's disease patients. 515-6 10.1111/ggi.12010 Satoh Sachiko S Kajiwara Mutsuko M Kiyokawa Emi E Toukairin Yoshiko Y Fujii Masahiko M Sasaki Hidetada H eng Comparative Study Letter Randomized Controlled Trial Japan Geriatr Gerontol Int 101135738 1447-0594 0 Cholinesterase (...) Inhibitors 0 Phenylcarbamates PKI06M3IW0 Rivastigmine IM Activities of Daily Living Aged, 80 and over Alzheimer Disease drug therapy psychology Behavioral Symptoms Cholinesterase Inhibitors administration & dosage Cognition drug effects Female Humans Interpersonal Relations Male Massage Mental Status Schedule Phenylcarbamates administration & dosage Rivastigmine Tomography, X-Ray Computed methods Transdermal Patch 2013 4 5 6 0 2013 4 5 6 0 2013 11 6 6 0 ppublish 23551354 10.1111/ggi.12010

2013 Geriatrics & gerontology international Controlled trial quality: uncertain

87. Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. (Abstract)

Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine.Total 56 patients aged 50-75 years, suffering from dementia, were allocated into one of the two treatments: group 1) Ginkgo biloba (120 mg daily dose); group 2) rivastigmine (4.5 mg daily dose) in a 24 (...) -week randomized double blind study. The degree of severity of dementia was assessed by the Seven Minute test and the Mini-Mental State Examination.Our results confirm the clinical efficacy of rivastigmine in the dementia of the Alzheimer type, comparing to Ginkgo biloba. There are few published trials that have directly compared a cholinesterase inhibitor with Ginkgo for dementia. This study directly compares a cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer type.Our study

2013 JPMA. The Journal of the Pakistan Medical Association Controlled trial quality: uncertain

88. Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis. Full Text available with Trip Pro

Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis. The cholinesterase inhibitor rivastigmine is approved for the treatment of mild to moderate Alzheimer's disease. However, it is not possible to predict which individuals will benefit from treatment. This retrospective analysis of an international, 24-week, randomized, double-blind trial aimed to identify the percentage of persons with Alzheimer's disease who have a sustained response (...) with rivastigmine patch, rivastigmine capsules, or placebo; to determine the magnitude of the sustained treatment response; and to investigate baseline patient characteristics predictive of the observed sustained response.Patients who improved on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL) at week 16 and maintained at least the week 16 improvement at week 24 were identified as sustained responders

2013 The Primary Care Companion for CNS Disorders Controlled trial quality: predicted high

89. Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. (Abstract)

Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine.Total 56 patients aged 50-75 years, suffering from dementia, were allocated into one of the two treatments: group 1) Ginkgo biloba (120 mg daily dose); group 2) rivastigmine (4.5 mg daily dose) in a 24 (...) -week randomized double blind study. The degree of severity of dementia was assessed by the Seven Minute test and the Mini-Mental State Examination.Our results confirm the clinical efficacy of rivastigmine in the dementia of the Alzheimer type, comparing to Ginkgo biloba. There are few published trials that have directly compared a cholinesterase inhibitor with Ginkgo for dementia. This study directly compares a cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer type.Our study

2013 JPMA. The Journal of the Pakistan Medical Association Controlled trial quality: uncertain

90. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease. (Abstract)

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease. Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD).Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD

2013 American journal of Alzheimer's disease and other dementias Controlled trial quality: uncertain

91. The effect of rivastigmine on the LPS-induced suppression of GnRH/LH secretion during the follicular phase of the estrous cycle in ewes. (Abstract)

The effect of rivastigmine on the LPS-induced suppression of GnRH/LH secretion during the follicular phase of the estrous cycle in ewes. This study was designed to determine the effect of a potent subcutaneously injected acetylcholinesterase inhibitor, rivastigmine (6mg/animal), on the gonadotropin-releasing hormone (GnRH)/luteinizing hormone (LH) release during inflammation induced by an intravenous lipopolysaccharide (LPS) (400ng/kg) injection in ewes during the follicular phase (...) of the estrous cycle. The results are expressed as the mean values from -2 to -0.5h before and +1 to +3h after treatment. Rivastigmine decreased the acetylcholinesterase concentration in the blood plasma from 176.9±9.5 to 99.3±15.1μmol/min/ml. Endotoxin suppressed LH (5.4±0.6ng/ml) and GnRH (4.6±0.4pg/ml) release; however, the rivastigmine injection restored the LH concentration (7.8±0.8ng/ml) to the control value (7.8±0.7ng/ml) and stimulated GnRH release (7.6±0.8pg/ml) compared to the control (5.9±0.4pg/ml

2013 Animal reproduction science Controlled trial quality: uncertain

92. Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease. Full Text available with Trip Pro

Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease. The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI) treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and either dementia or mild cognitive impairment underwent task-free functional magnetic resonance imaging before and after 3 months of ChEI treatment and were compared with 15 age- and sex-matched neurologically healthy (...) with cognitive impairment show numerous regions of decreased spontaneous brain function compared with controls, and rivastigmine is associated with performance-related normalization in the left frontal cortex function.© 2013 International Parkinson and Movement Disorder Society.

2013 Movement Disorders

93. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. (Abstract)

Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. Even with optimal dopaminergic treatments, many patients with Parkinson's disease (PD) are frequently incapacitated by apathy prior to the development of dementia. We sought to establish whether rivastigmine's ability to inhibit acetyl- and butyrylcholinesterases could relieve the symptoms of apathy in dementia-free, non-depressed patients (...) with advanced PD.We performed a multicentre, parallel, double-blind, placebo-controlled, randomised clinical trial (Protocol ID: 2008-002578-36; clinicaltrials.gov reference: NCT00767091) in patients with PD with moderate to severe apathy (despite optimised dopaminergic treatment) and without dementia. Patients from five French university hospitals were randomly assigned 1:1 to rivastigmine (transdermal patch of 9.5 mg/day) or placebo for 6 months. The primary efficacy criterion was the change over time

2013 Neurosurgery and Psychiatry Controlled trial quality: predicted high

94. A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia. Full Text available with Trip Pro

A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia. The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD).Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD

2013 CNS neuroscience & therapeutics Controlled trial quality: predicted high

95. Rivastigmine for vascular cognitive impairment. (Abstract)

Rivastigmine for vascular cognitive impairment. Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia broadly follows three clinico-pathological processes: multi-infarct dementia, single strategic infarct dementia and subcortical dementia. Not all victims fulfil strict (...) criteria for dementia and may be significantly cognitively impaired without memory loss, when the term vascular cognitive impairment (VCI) is more useful. Currently, no established standard treatment for VCI exists. Reductions in acetylcholine and acetyltransferase activity are common to both Alzheimer's disease and VCI, raising the possibility that cholinesterase inhibitors - such as rivastigmine - which are beneficial in Alzheimer's disease, may also be beneficial for VCI.To assess the efficacy

2013 Cochrane database of systematic reviews (Online)

96. Rivastigmine for HIV-associated neurocognitive disorders: A randomized crossover pilot study. Full Text available with Trip Pro

Rivastigmine for HIV-associated neurocognitive disorders: A randomized crossover pilot study. To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by placebo (20 weeks) or placebo (...) followed by rivastigmine. Efficacy endpoints were improvement on rivastigmine in the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) and individual neuropsychological scores of information processing speed, attention/working memory, executive functioning, and motor skills. Measures of safety included frequency and nature of adverse events and abnormalities on laboratory tests and on plasma concentrations of antiretroviral drugs. Analyses of variance with repeated measures were

2013 Neurology Controlled trial quality: predicted high

97. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. (Abstract)

Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Cognitive decline has been recognised as a frequent symptom in multiple sclerosis (MS). Cholinesterase inhibitors (ChEIs) are employed for the treatment of Alzheimer's disease, but there is some evidence that ChEIs might also be effective in MS patients with cognitive deficits, particularly deficits of memory function.The aim of this study was to evaluate efficacy on memory (...) function and safety of the ChEI rivastigmine in MS patients with cognitive deficits as measured by the change from baseline of the total recall score of the selective reminding test (SRT) after 16 weeks of treatment.Efficacy and safety of rivastigmine were analysed in a 16-week, multicentre, double-blind, randomised, placebo-controlled study, followed by an optional one-year open-label treatment phase. Effects of rivastigmine and placebo were compared by an analysis of covariance.In total, 86 patients

2013 Multiple sclerosis (Houndmills, Basingstoke, England) Controlled trial quality: uncertain

98. Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer's Disease Treated with Rivastigmine. (Abstract)

Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer's Disease Treated with Rivastigmine. Poor adherence to anti-dementia drugs is common among patients with Alzheimer's disease. This study evaluated whether caregivers were more satisfied with, and patients more adherent to, transdermal rivastigmine than oral rivastigmine.Neurologists, psychiatrists and geriatricians collected sociodemographic and clinical data from 1,078 patients (...) and administered the Treatment Satisfaction with Medicines (SATMED-Q) and the Morisky-Green questionnaires to their caregivers at outpatient consultations.Satisfaction reported was greater with transdermal than oral rivastigmine: mean ± SD of the total SATMED-Q score, 72.5 ± 14.1 vs. 65.2 ± 12.5, p < 0.001. The proportion of adherent patients was greater with transdermal than with oral rivastigmine (65.0 vs. 41.4%, p < 0.001). Satisfaction, in turn, was significantly greater in adherent cases than

2013 Dementia and Geriatric Cognitive Disorders Controlled trial quality: uncertain

99. Rivastigmine (Exelon) transdermal patch: risk of medication errors

Rivastigmine (Exelon) transdermal patch: risk of medication errors Rivastigmine (Exelon) transdermal patch: risk of medication errors - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Rivastigmine (Exelon) transdermal patch: risk of medication errors Medication errors and inappropriate use of the rivastigmine transdermal patch have been reported, some of which resulted in overdose. Healthcare professionals should be aware of the correct use of rivastigmine, and should advise (...) patients and caregivers as outlined in this article. Published 11 December 2014 From: Therapeutic area: Contents Rivastigmine (Exelon) transdermal patch is indicated for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia. The patch is available in two doses: 4.6 mg/24 hours; and 9.5 mg/24 hours. Treatment is started with one 4.6 mg/24 hour patch. After a minimum of 4 weeks and if tolerated well, the daily dose should be increased to the recommended effective dose of 9.5 mg/24

2010 MHRA Drug Safety Update

100. Rivastigmine

Rivastigmine Rivastigmine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Rivastigmine Rivastigmine Aka: Rivastigmine , Exelon II (...) . Indications III. Mechanism See -based noncompetitive Inhibits butyrylcholinesterase and acetylcholinesterase Increases transmission IV. Pharmacokinetics: Oral Route Peak: 1 hour Duration: 10 hours V. Drug Interactions No significant s VI. Efficacy Modestly improves scores on s Benefits decrease after 40 weeks of treatment VII. Adverse Effects See Specific adverse effects reported for Rivastigmine, not seen with other s VIII. Dosing Oral Route Initial: 1.5 mg orally twice daily with food for at least 2

2015 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>